STOCK TITAN

If You Invested in Genmab A/S (GNMSF)

Healthcare · Biotechnology · OTC Link
Looking for the current price? See the GNMSF quote & overview
$1,000 invested 1 Year Ago
$1,301
+30.1% total 30.5% CAGR
Bought on Jul 17, 2025 at $219.75
$1,000 invested 5 Years Ago
N/A
Trading since 2021-12-31

What $1,000 or $10,000 in GNMSF Would Be Worth Today

Real historical value by amount invested and how long ago
If you invested 1 year ago 5 years ago 10 years ago Since Dec 31, 2021
$1,000 $1,301 +30% $732 -27%
$10,000 $13,008 +30% $7,320 -27%

Based on real historical closing prices through the latest market close. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for GNMSF

$1,000 Investment Over Time

GNMSF vs S&P 500

Year-by-Year Returns

GNMSF annual performance
Year Start Price End Price Annual Return Cumulative
2021 $390.53 $390.53 +0.0% +0.0%
2022 $402.58 $427.50 +6.2% +9.5%
2023 $432.11 $315.70 -26.9% -19.2%
2024 $318.10 $207.38 -34.8% -46.9%
2025 $209.72 $314.00 +49.7% -19.6%
2026 $323.68 $285.85 -11.7% -26.8%

About Genmab A/S

Healthcare · OTC Link

Genmab A/S (GNMSF) is a foreign private issuer whose securities are associated with the ticker GNMSF. According to its regulatory disclosures, Genmab A/S files reports with the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934 as a non‑U.S. company. The company uses Form 6-K to furnish current reports and references multiple registration statements on Form S-8, indicating that it has registered securities for employee or related compensation plans.

In an SEC filing identified as a Form 6-K for the month of September 2025, Genmab A/S states that the report is furnished pursuant to Rule 13a-16 or 15d-16 of the Exchange Act. The filing also specifies that the Form 6-K is deemed to be incorporated by reference into several of the company’s existing Form S-8 registration statements. This linkage shows how Genmab A/S integrates its ongoing current reports into its broader U.S. securities registration framework.

Genmab A/S is based in Denmark, with its address in Valby, Denmark, as disclosed in the Form 6-K. The filing further notes that the company files annual reports under cover of Form 20-F or Form 40-F, and includes a check-box section for this purpose. This confirms that Genmab A/S follows the foreign issuer reporting regime rather than the domestic U.S. issuer framework.

The September 2025 Form 6-K includes an exhibit index listing a Company Announcement: Major Shareholder Announcement and a Standard form for notification of major holdings. This indicates that Genmab A/S provides market updates related to significant shareholdings and uses standardized notification formats for major holdings, which can be relevant for investors monitoring changes in substantial ownership positions.

Because the available information is drawn from a specific SEC filing, detailed information about the company’s industry, sector, products, or services is not provided here. Investors researching GNMSF can use this overview as a starting point to understand that Genmab A/S is a Denmark-based foreign issuer with securities registered in the United States and that it communicates major shareholder information through Form 6-K exhibits.

Market Cap
$17.5B
Current Price
$285.85
Revenue
$3.7B
Net Margin
25.9%
View full GNMSF overview

Frequently Asked Questions

Genmab A/S investment returns

How much would $1,000 invested in Genmab A/S be worth today?

If you invested $1,000 in Genmab A/S (GNMSF) 1 years ago on 2025-07-17, your investment would be worth $1,301 today, representing a +30.1% total return, growing at a compounded rate of 30.5% per year (CAGR).

Has Genmab A/S outperformed the S&P 500?

Comparison data requires at least 10 years of trading history. Use the calculator above to compare GNMSF performance over available time periods.

What is Genmab A/S's average annual return?

The compound annual growth rate (CAGR) of GNMSF over the past 1 years is 30.5%, growing at a compounded rate each year. Individual years vary significantly — GNMSF's best recent year was 2025 (+49.7%) and worst was 2024 (-34.8%).

Your Privacy is Protected

This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.

Server-Assisted No Saved Calculator Data Historical Market Data

For informational and educational purposes only — not investment advice.